AI Article Synopsis
- - Recent findings indicate that gefitinib, an EGFR-TKI, significantly improves performance status in patients with EGFR mutations who initially have a very poor status.
- - EGFR mutations are common in east-Asian, female, non-smokers with adenocarcinoma, but can also be found in smokers and non-adenocarcinoma cases.
- - A specific case is highlighted where a male, current smoker with squamous cell carcinoma showed a strong positive response to first-line gefitinib therapy, suggesting the need for EGFR testing even in SCC patients, particularly among east-Asians.
Article Abstract
Recent reports have shown gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) induced marked improvement in ECOG performance status (PS) as first-line therapy in EGFR mutation-positive patients with extremely poor PS. EGFR mutations frequently occur in east-Asian, female, non-smoking, adenocarcinoma patients, however they are occasionally detected in patients with non-adenocarcinomas or with a heavy smoking history. We describe a case in which EGFR mutation was detected in a male, current smoker, squamous cell carcinoma (SCC) patient with PS 4, who showed a marked response to the first-line gefitinib therapy. EGFR mutational analysis is recommended even for SCC patients especially in east-Asian populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.51.6386 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!